Literature DB >> 35238051

Controlling ion channel function with renewable recombinant antibodies.

Henry M Colecraft1, James S Trimmer2.   

Abstract

Selective ion channel modulators play a critical role in physiology in defining the contribution of specific ion channels to physiological function and as proof of concept for novel therapeutic strategies. Antibodies are valuable research tools that have broad uses including defining the expression and localization of ion channels in native tissue, and capturing ion channel proteins for subsequent analyses. In this review, we detail how renewable and recombinant antibodies can be used to control ion channel function. We describe the different forms of renewable and recombinant antibodies that have been used and the mechanisms by which they modulate ion channel function. We highlight the use of recombinant antibodies that are expressed intracellularly (intrabodies) as genetically encoded tools to control ion channel function. We also offer perspectives of avenues of future research that may be opened by the application of emerging technologies for engineering recombinant antibodies for enhanced utility in ion channel research. Overall, this review provides insights that may help stimulate and guide interested researchers to develop and incorporate renewable and recombinant antibodies as valuable tools to control ion channel function.
© 2022 The Authors. The Journal of Physiology © 2022 The Physiological Society.

Entities:  

Keywords:  antibody; intrabody; ion channel modulation; nanobody; scFv

Mesh:

Substances:

Year:  2022        PMID: 35238051      PMCID: PMC9058206          DOI: 10.1113/JP282403

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   6.228


  83 in total

1.  Getting to reproducible antibodies: the rationale for sequenced recombinant characterized reagents.

Authors:  Andrew R M Bradbury; Andreas Plückthun
Journal:  Protein Eng Des Sel       Date:  2015-10       Impact factor: 1.650

2.  Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity.

Authors:  David Gómez-Varela; Esther Zwick-Wallasch; Hendrik Knötgen; Araceli Sánchez; Thore Hettmann; Dmitri Ossipov; Rüdiger Weseloh; Constanza Contreras-Jurado; Mike Rothe; Walter Stühmer; Luis A Pardo
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

3.  The fibronectin type III domain as a scaffold for novel binding proteins.

Authors:  A Koide; C W Bailey; X Huang; S Koide
Journal:  J Mol Biol       Date:  1998-12-11       Impact factor: 5.469

Review 4.  Monoclonal antibody therapeutics: history and future.

Authors:  Nicholas A P S Buss; Simon J Henderson; Mary McFarlane; Jacintha M Shenton; Lolke de Haan
Journal:  Curr Opin Pharmacol       Date:  2012-08-21       Impact factor: 5.547

5.  Molecular Structure of the Human CFTR Ion Channel.

Authors:  Fangyu Liu; Zhe Zhang; László Csanády; David C Gadsby; Jue Chen
Journal:  Cell       Date:  2017-03-23       Impact factor: 41.582

6.  Recombinant Antibodies in Basic Neuroscience Research.

Authors:  James S Trimmer
Journal:  Curr Protoc Neurosci       Date:  2020-12

7.  Beta subunits promote K+ channel surface expression through effects early in biosynthesis.

Authors:  G Shi; K Nakahira; S Hammond; K J Rhodes; L E Schechter; J S Trimmer
Journal:  Neuron       Date:  1996-04       Impact factor: 17.173

Review 8.  Antibodies and venom peptides: new modalities for ion channels.

Authors:  Heike Wulff; Palle Christophersen; Paul Colussi; K George Chandy; Vladimir Yarov-Yarovoy
Journal:  Nat Rev Drug Discov       Date:  2019-05       Impact factor: 84.694

9.  Autoimmune channelopathies of the nervous system.

Authors:  Kleopas A Kleopa
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

10.  Structure of a pore-blocking toxin in complex with a eukaryotic voltage-dependent K(+) channel.

Authors:  Anirban Banerjee; Alice Lee; Ernest Campbell; Roderick Mackinnon
Journal:  Elife       Date:  2013-05-21       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.